Skip to content

A Cohort Study on the Efficacy of TCM Stage-Based Therapy in Improving Survival Outcomes for Patients with Metastatic Colon and Rectal Cancer

A Cohort Study on the Efficacy of TCM Stage-Based Therapy in Improving Survival Outcomes for Patients with Metastatic Colon and Rectal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001663
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Exposure group:Combined with Western medical treatment, patients received at least 3 months of stage-based Chinese medical treatment.
Non-exposure group:Receiving standard-of-care Western medical treatment

Sponsors

Xi yuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria for Study Participants (1)Age =18 years old(2)Pathologically diagnosed with metastatic colon and rectal cancer and classified as Clinical Stage IV. (3)No restriction on treatment phase (e.g. first-line second-line or salvage therapy(4)ECOG Performance Status 0-2(5) Expected survival =3 months(6)Measurable lesions meetingRECIST 1.1 criteria(7)No severe cardiovascular respiratory hepatic or renal dysfunction (e.g. left ventricular ejection fraction =50% Child-Pugh score =7 CrCl =30 mL/min)(8)Normal coagulation function (e.g. PT/APTT within normal range) and no active bleeding orthrombotic disorders(9)Capable of adhering to the protocol for follow-up evaluations of efficacy and adverse reactions.

Exclusion criteria

Exclusion criteria: Exclusion Criteria for Study Participants (1)Patients with clinical manifestations of brain metastases;(2)Patients with concurrent that have not been fully treat ed; (3)Patients with defective mismatch repair (dMMR) as confirmed by immunohistochemistry or microsatellite instability-high (MSI-H) status verified by genetic testing;(4)Patients whose general medical condition render them unsuitable for conventional Western anti-tumor therapy;(5)Patients planning to participate or currently participating in other clinical trials;(6)Patients with conditions deemed unsuitable for inclusion by researchers such as pregnancy;(7)Patients whose medical records document a prior refusal to use their case for research purposes.

Design outcomes

Primary

MeasureTime frame
Overall Survival;

Secondary

MeasureTime frame
maintenance progression free survival; Annual OS rates;Disease Duration Control;Lines of Therapy;Disease Control Rate;Time of TCM intervention;

Countries

China

Contacts

Public ContactZhang Tong

Xi yuan Hospital of CACMS

ashtray7654@126.com18710047520

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026